Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

ERK-1/2 inhibitor GIZH298 demonstrates antiseizure effects in vivo

July 14, 2021

Qixleef phase II protocol modifications approved

July 13, 2021

Prokineticin-2 as therapeutic target for prevention of neuronal death

July 13, 2021

New protein O-GlcNAcase inhibitors discovered at Janssen Pharmaceutica

July 12, 2021

Bioasis reports outcome of preclinical study of xB3-IL-1RA for MS

July 9, 2021

Janssen Pharmaceutica discloses new OGA inhibitors

July 9, 2021

Ischemix awarded DoD funding to support phase I study of CMX-2043 for traumatic brain injury

July 8, 2021

To close or not to close: Astrocytes influence brain plasticity by controlling critical period

July 8, 2021

SciSparc to initiate phase II study of SCI-110 in patients with AD and agitation

July 8, 2021

Sorrento cleared in U.S. to begin phase II study of resiniferatoxin in knee osteoarthritis pain

July 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...